Oncternal Therapeutics Inc (NAS:ONCT)
$ 8.18 0.08 (0.99%) Market Cap: 24.21 Mil Enterprise Value: -2.54 Mil PE Ratio: 0 PB Ratio: 1.06 GF Score: 39/100

Oncternal Therapeutics Inc Host Key Opinion Leader Webinar Transcript

Jan 25, 2022 / 07:30PM GMT
Release Date Price: $38.2 (-1.04%)
Operator

Good afternoon, and welcome to the Oncternal Therapeutics KOL webinar on hematological malignancies and prostate cancer. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Oncternal website following the conclusion of the event.

I'd now like to turn the call over to your host, Dr. Mr. Jim Breitmeyer, President and Chief Executive Officer of Oncternal. Please go ahead, Jim.

James B. Breitmeyer
Oncternal Therapeutics, Inc. - President, CEO & Director

Thank you, Pauline, and it's my pleasure to welcome you all to Oncternal's R&D day and our focus on hematologic malignancies and prostate cancer.

So if I can have the next slide. This is the agenda. The first half of the present presentation will focus on Heme Malignancies with our speaker, Dr. Michael Wang from MD Anderson and then Oncternal management will provide an update of the zilovertamab antibody program and the ROR1 cell therapy program. A Q&A will follow that section.

Then in the second half, we will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot